Heartbeam
Logotype for Heartbeam Inc

Heartbeam (BEAT) investor relations material

Heartbeam Q2 2026 earnings summary

Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.
Logotype for Heartbeam Inc
Q2 2026 earnings summary13 Aug, 2026

Executive summary

  • Advanced heart attack detection initiatives with clinical validation ahead of schedule, including completed enrollment in ALIGN-ACS and over 50% enrollment in HEADSTART-ACS pilot studies; FDA pre-submission completed and new product form factors developed.

  • Initial commercial launch underway, targeting concierge practices and integrated network partnerships, with multiple agreements signed in four U.S. regions and positive feedback from physicians and patients.

  • Proprietary TriCor 3D signal reconstruction technology embedded in multiple form factors, protected by 25+ issued patents worldwide, with recent additions expanding acoustic sensing and fluid monitoring capabilities.

  • Strategic shift to licensing technology and expanding into international markets, notably Indonesia, with pilot studies and partnerships supporting future growth.

  • Leadership changes implemented, with the founder assuming principal executive officer duties following CEO and board member departures.

Financial highlights

  • Net cash used in operating activities was $3.3 million for Q2 2026, a 7% decrease from Q1 2026 and a 3% decrease year-over-year.

  • Net loss for Q2 2026 was $5.0 million, or $(0.10) per share, including one-time items; adjusted net loss was $4.1 million, down 12% sequentially and 17% year-over-year.

  • Cash, cash equivalents, and restricted cash totaled $8.8 million as of June 30, 2026, following an $11.5 million capital raise in April.

  • Operating expenses for Q2 2026 were $5.1 million, with SG&A at $2.8 million and R&D at $2.3 million.

  • No revenue generated for the three and six months ended June 30, 2026.

Outlook and guidance

  • Cash runway extended into 2027 due to reduced cost profile and capital raise, supporting continued execution of strategic priorities.

  • Operating cash outflows expected to trend below $14 million for full year 2026, with Q4 baseline spend projected under $2.5 million per quarter.

  • Management expects no material commercial revenue in 2026 and ongoing operations depend on raising additional capital.

  • Pivotal heart attack detection trial anticipated to begin before year-end, pending FDA feedback.

  • Break-even point estimated at fewer than 30,000 patients, with current contracts covering thousands and significant growth potential in major U.S. geographies.

Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.
Research faster. Power your platform.

Next Heartbeam earnings date

Logotype for Heartbeam Inc
Q3 202612 Nov, 2026
Heartbeam
Cover every name on your watchlist this earnings season.
Automations, AI chat, and live calls across 16,000+ companies.
Book demo

Next Heartbeam earnings date

Logotype for Heartbeam Inc
Q3 202612 Nov, 2026

AI chat

Ask anything. Verify everything.

Ask across every event and document from public companies. Each answer links back to the exact line in the transcript, slide or filing it came from.Learn more

Find what matters

AI across all first-party IR material. Live calls, transcripts, slides, filings.
A cited source card from Adobe's CFO alongside a list of forward-looking statements

Trust every finding

50m+ first-party documents. Every output traceable to its source.

Automations

Zero in on what matters

Define the prompt once. It runs the moment a company publishes or on a schedule you set. Outputs map to the exact signals you choose.Learn more
An automation set to trigger on the first published earnings document for GE Aerospace

Event-triggered research

Runs when a company publishes new material. Trigger on the first published document for the earliest possible run, or wait for a specific one.
An automation scheduled to run weekly on Mondays at 09:00

Scheduled research

Runs on a recurring cadence you set. Daily, weekly, monthly, or quarterly, for aggregate reads across a period rather than a single event.

Live audio & transcripts

Be first

Join any earnings call live in one click, with no manual registration. Follow the transcript as it happens and jump straight to the moments that matter.Learn more
A live LVMH Q2 2026 earnings call playing in Quartr

Live earnings calls

Join any call in one click. The audio keeps playing while you work elsewhere in Quartr.
A live transcript excerpt from LVMH's Chairman and CEO Bernard Arnault

Live transcripts

Speaker-by-speaker, in real time. Searchable across every live and historical call.

Quartr MCP connects your AI environment to 17K+ public companies

Pull live transcripts, filings, and slides into Claude or Codex via MCP. Combine Quartr's global IR data with any other dataset. Run agentic research and monitoring.
Included with Quartr Pro at no extra cost.Learn more

Quartr's AI stands out because it only pulls clean, first-party data from public companies. In investing, that's everything.

Jamie Ross

Investment Manager, GAM Investments

GAM
GAM

Research that used to take hours now takes seconds with Quartr Pro. Tracking shifts in tone or extracting tables, it's as simple as typing a query.

Tom O'Hara

Investment Director

Ciena
Ciena

Before Quartr we spent hours manually compiling insights through the peer earnings cycle. Now, these tasks are done faster, with greater precision.

Gregg Lampf

VP of Investor Relations

Frequently asked questions

HeartBeam, Inc. is a medical technology company focused on developing innovative cardiac care solutions. The company’s primary product is a proprietary 3D-vector ECG platform designed to assist in the detection and diagnosis of heart attacks and other cardiac conditions. HeartBeam aims to provide more accurate and accessible cardiac care tools, enabling healthcare professionals to monitor and diagnose heart-related issues in both clinical and remote settings. The company serves the healthcare industry, particularly in the fields of cardiology and emergency medicine, with a focus on improving diagnostic accuracy and patient outcomes. The company is headquartered in Santa Clara, California, and its shares are listed on the NASDAQ.